Abstract
Purpose: :
To evaluate patient outcomes following Epithelium-On CXL in patients over the age of 35.
Methods: :
This prospective, non-randomized trial evaluated patients who underwent epithelial-ON CXL. A subgroup of patients over the age of 35 was evaluated for this analysis. Post-Op measures included corneal hysteresis (CH) and corneal resistance factor (CRF), Pentacam data, and uncorrected and best-spectacle corrected visual acuities. Eyes evaluated had a minimum follow-up visit of 3 months and a maximum follow up visit of 12.8 months.
Results: :
90 eyes met the entry criteria (65 male, 22 female), with a follow up range of 3 months minimum to 12.8 months maximum. The mean follow up was 7.9 months. 67% of these eyes had a pre-op diagnosis of keratoconus, 20% had post-LASIK Ectasia, and 3% had pellucid marginal degeneration. Average CH and CRF values increased post-Operatively from 7.7 to 8.0 and 6.5 to 8.0, respectively, at the latest follow up visit. Average refractive cylinder decreased from 4.59 D to 4.15D. On Pentacam the average 2mm K Astigmatism decreased from 5.94 to 4.71 and Holladay Astigmatism decreased from 3.31 to 2.26. 34.8% of eyes experienced no change in the number of lines of BSCVA and 46% of eyes gained 1 or more lines of BSCVA. Average BSCVA pre-Op was 20/163 and post-Op was 20/109.
Conclusions: :
Epithelial-on cross-linking appears to be safe and effective for patients of age 35 and over with ectatic corneal disease.
Clinical Trial: :
http://www.clinicaltrials.gov NCT01024322